NSCLC Clinical Trials in Beijing, Beijing Municipality
26 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 26 trials
Recruiting
Phase 3
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Non-small Cell Lung Cancer (NSCLC)
Nuvation Bio Inc.180 enrolled29 locationsNCT07154706
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled255 locationsNCT07361497
Recruiting
Phase 2
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
MTAP-deleted NSCLC
Amgen200 enrolled91 locationsNCT06593522
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled205 locationsNCT06422143
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC520 enrolled156 locationsNCT06305754
Recruiting
Phase 3
IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed
iO Resistant sqNSCLC
Fortvita Biologics (USA)Inc.600 enrolled42 locationsNCT07217301
Recruiting
Phase 2
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Solid Tumor+1 more
Guangzhou JOYO Pharma Co., Ltd210 enrolled1 locationNCT06895031
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC556 enrolled192 locationsNCT06074588
Recruiting
Phase 3
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR
Allist Pharmaceuticals, Inc.300 enrolled2 locationsNCT06956001
Recruiting
Phase 2
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd.66 enrolled18 locationsNCT06924606
Recruiting
Phase 1Phase 2
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Endometrial CancerGastric (Stomach) CancerNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Beijing Tide Pharmaceutical Co., Ltd266 enrolled3 locationsNCT07371663
Recruiting
Not Applicable
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
NSCLC
Peking Union Medical College150 enrolled1 locationNCT07247227
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy
Lung Cancer (NSCLC)
Beijing Haidian Hospital30 enrolled1 locationNCT07257471
Recruiting
Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
Lung Cancer (NSCLC)
Beijing Haidian Hospital30 enrolled1 locationNCT07257458
Recruiting
Not Applicable
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
NSCLC
Peking University Cancer Hospital & Institute286 enrolled1 locationNCT06924710
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
NSCLCAdjuvant Treatment
Allist Pharmaceuticals, Inc.338 enrolled2 locationsNCT07010419
Recruiting
Phase 1
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
NSCLC (Advanced Non-small Cell Lung Cancer)
Peking University Cancer Hospital & Institute21 enrolled1 locationNCT06969612